Aster DM Healthcare, one of the largest integrated healthcare providers in the Middle East, has signed a Memorandum of Understanding (MoU) with Novartis, a leading global medicines company, to collaborate on digital transformation and clinical research.
The MoU will allow Aster to access Novartis’ advanced therapy platforms and data science to further strengthen treatment outcomes for patients in UAE and beyond.
The partnership seeks to identify the current gaps in patient care and introduce extensive medical programs using innovative data platforms and data syndicated designs. This is in line with Aster’s long-term plan to combine clinical research and digital transformation into its operations in the country which will have an impact on the clinical outcome delivery for patients.
“Data Analytics with focus on clinical research is one of the cornerstones of healthcare in the future. Aster tries to stay ahead of the curve in offering the best medical solutions to our patients and equipping our doctors with the most advanced systems to be able to do so. We have associated with Novartis in the past and are glad to enter into a multi-faceted partnership to enhance digital transformation and research.”
In line with the MoU, Novartis will allow data generation, ideation, and impactful decision-making for Aster DM Healthcare’s clinical research program. The organizations have plans to create a series of workshops, training, and educational activities, which will assist Aster to start its activities on clinical research.
The digital transformation initiatives will also separately work on boosting the digital healthcare strategy of Aster for its market in the UAE and beyond, whereas Novartis will offer its expertise and share best practices.
“We truly believe that we share a common vision, and we are confident that this partnership has the potential to add value and have an impact on patients in UAE. We are happy to collaborate with Aster to realize their vision towards data transformation and clinical research, both of which are tantalizing growth areas for the healthcare sector,” said Mr. Mohamed Ezz Eldin, President and Head of Gulf Cluster, Novartis Pharmaceuticals.